Anavex Life Sciences (AVXL) – Company Press Releases
-
AVXL INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Anavex Life Sciences Corporation Investors with Substantial Losses Have Opportunity to Lead Case
-
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Anavex
-
ANAVEX LIFE SCIENCES CORPORATION (NASDAQ: AVXL) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Anavex Life Sciences Corporation Investors of Upcoming Deadline
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, and Checkpoint and Encourages Investors to Contact the Firm
-
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Anavex
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, Checkpoint, and Sonder and Encourages Investors to Contact the Firm
-
ANAVEX LIFE SCIENCES CORPORATION (NASDAQ: AVXL) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against An
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, and Checkpoint and Encourages Investors to Contact the Firm
-
Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, and Anavex and Encourages Investors to Contact the Firm
-
Robbins LLP Reminds Investors to Seek Counsel in the Class Action Against Anavex Life Sciences Corporation (AVXL)
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hut 8, Ventyx, and Anavex and Encourages Investors to Contact the Firm
-
ANAVEX LIFE SCIENCES CORPORATION (NASDAQ: AVXL) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against An
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hut 8, Anavex, and Innoviz and Encourages Investors to Contact the Firm
-
DEADLINE ALERT: Bernstein Liebhard LLP Reminds Anavex Life Sciences Corporation Investors of Upcoming Deadline
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hut 8, Anavex, and Innoviz and Encourages Investors to Contact the Firm
-
ANAVEX LIFE SCIENCES CORPORATION (NASDAQ: AVXL) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against An
-
AVXL INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Anavex Life Sciences Corporation Investors with Substantial Losses Have Opportunity to Lead Case
-
Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hut 8, Anavex, and Innoviz and Encourages Investors to Contact the Firm
-
AVXL Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Anavex Life Sciences Corporation Class Action
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hut 8, and Anavex and Encourages Investors to Contact the Firm
-
ANAVEX LIFE SCIENCES CORPORATION (NASDAQ: AVXL) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against An
-
Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
-
AVXL INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Anavex Life Sciences Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
ANAVEX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Anavex Life Sciences Corp. and Encourages Investors to Contact the Firm
-
Investor Notice: Robbins LLP Informs Investors of Class Action Filed Against Anavex Life Sciences Corporation (AVXL)
-
ANAVEX LIFE SCIENCES CORPORATION SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Anavex Life Sciences Corporation (NASDAQ: AVXL)
-
AVXL INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Anavex Life Sciences Corporation Investors with Substantial Losses Have Opportunity to Lead the Anavex Class Action Lawsuit
-
Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference
-
Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update
-
Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024
-
Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX®3-71 in Humans
-
Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
-
Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders
-
Anavex to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Anavex Life Sciences Provides an Update on Rett Syndrome Program
-
Anavex Announces First Entire Clinical Gene Pathway Data of ANAVEX®2-73 from AVATAR Study in Patients with Rett Syndrome
-
Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer’s Disease
-
Anavex Life Sciences Reports Fiscal 2023 Year End Financial Results and Provides Business Update
-
Anavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023
-
Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Insomnia or Anxiety
-
Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease to European Medicines Agency (EMA)
-
Anavex Life Sciences Appoints Senior VP of Regulatory Affairs
-
Anavex Life Sciences Reports New Publication in Scientific Journal Demonstrating the Potential of ANAVEX®3-71 to Prevent Cognitive Decline in Alzheimer’s Disease
-
Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration
-
Anavex Announces Appointment of Dr. Marwan N Sabbagh, MD as Chairman of the Scientific Advisory Board
-
Anavex Life Sciences Reports Fiscal 2023 Third Quarter Financial Results
-
Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming ANAVEX®3-71 Clinical Cardiovascular Safety
-
Anavex Life Sciences to Present at the BTIG Virtual Biotechnology Conference 2023
Back to AVXL Stock Lookup
